The prospects of tumor necrosis factor α inhibitors use in patients with covid-19

0Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

The review highlights the problem of finding new effective treatment strategies for COVID-19. Tumor necrosis factor α (TNF-α) is considered as a therapeutic target. The theoretical basis for the successful use of TNF-α inhibitors (ITNFα) for the treatment of COVID-19 is presented, as well as data on existing practical developments, including ongoing clinical trials. Two drugs from the group of ITNFα – infliximab and adalimumab – are currently being considered as possible options. The safety issues of ITNFα treatment in patients with immunophaling rheumatic diseases and COVID-19 are discussed. The review also provides current data on vaccination against COVID-19, in particular on the vaccines currently available in Russia, which are at different stages of clinical trials. We conclude that randomized clinical trials of the effectiveness and safety of ITNF-α in patients with the new coronavirus infection are needed. Such trials will promote transition from theoretical speculations to real clinical practice.

Cite

CITATION STYLE

APA

Aronova, E. S., & Belov, B. S. (2021). The prospects of tumor necrosis factor α inhibitors use in patients with covid-19. Sovremennaya Revmatologiya, 15(2), 89–93. https://doi.org/10.14412/1996-7012-2021-2-89-93

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free